Breast Cancer

In the ASCENT-07 trial, Trodelvy after endocrine therapy did not improve progression-free survival vs chemotherapy in HR+/HER2- metastatic breast cancer.

How a beloved childhood toy, a visionary inventor and one grandmother’s journey reveal the quiet strength of survival and the beauty found in every scar.

This year’s Breast Cancer Awareness Month highlighted FDA approvals, survivorship challenges and advances in breast reconstruction.

Learn how HR-positive/HER2-negative breast cancer is diagnosed, treated by stage and managed for side effects to guide patient-oncologist discussions.

An 11-year survivor of stage 4 breast cancer explains that everyone has a role to play.

CURE spoke with an areola tattoo artist and a patient who has undergone the procedure.

A cancer survivor explains how humor helped her during her cancer journey.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

Cancer has taught me to be vigilant, but also to be grateful — for modern science, for watchdog organizations and for the ability to access information instantly.

It wasn’t that I never expected a breast cancer diagnosis, it was that I had never even considered a breast cancer diagnosis.

For Stephanie Wachtel, receiving a diagnosis of triple-positive breast cancer at the age of 23 was life-changing in a number of ways.

Therapies may affect ovarian function and cause early menopause, and many younger women can still pursue family planning with guidance from their care team.

CURE spoke with experts about possible side effects faced by patients with breast cancer.

Eleven years after surviving breast cancer, I found a new lump that reignited old fears, reminding me that faith and vigilance remain vital to survivorship.

Going to a social event two weeks ago gave me perspective on my cancer experience and took me back to my childhood, when I never dreamt I’d grapple with the disease.

Denial is a very powerful thing, but it is one that can have serious negative consequences.

The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.

Shopping for prostheses reminded me of being in a very popular old toy store.

Breast cancer survivors highlighted guidance and encouragement they received when first diagnosed, offering reassurance for those who are newly diagnosed.

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.